Five scientists helping Neuroendocrine Tumor Research Foundation (NETRF) advance treatments of neuroendocrine tumors (NETs) have been named among the most influential in the world for 2018. Clarivate Analytics identifies the most influential researchers by the number of citations they receive in their field for the year. The five researchers are:
• Hans Clevers, MD, PhD, Royal Netherlands Academy of Arts and Sciences, Netherlands, principal investigator of a NETRF multi-year, $1.2 million Accelerator Award to create mini-organs in laboratory dishes (organoids) of NETs for drug testing.
• Matthew Meyerson, MD, PhD, Harvard University, Dana-Farber Cancer Center, Broad Institute, USA, is the principal investigator of a NETRF Accelerator Award aimed at identifying genomic and epigenetic causes of small intestinal NETs.
• Carl June, MD, University of Pennsylvania, USA, is part of a team of researchers that evaluated CAR T-cell therapy in NETs.
• Bradley Bernstein, MD, PhD, Massachusetts General Hospital, USA. evaluated epigenetic drivers in NETs.
• Todd Golub, MD, Broad Institute, USA, has served as a member of NETRF’s Board of Scientific Advisors.
NETRF, a leading funder of NET research says it counts on elite, world-class scientific minds to accelerate progress in NETs. “Our understanding of neuroendocrine tumors lags behind other cancer types,” said Elyse Gellerman, NETRF Chief Executive Officer. “We’re proud to work with these internationally recognized experts to search for cures and better. treatments for NETs.”
Read more here